“Stroke Drug Development: Bridging the Gap from Animal Research to Human Trials”
Orlando (Lake Buena Vista) Florida
March 6-7 1999

—— Dedicated to the Memory of Julio H. Garcia, MD ——

Conference Agenda

Saturday, March 6th

8:00 AM WELCOME AND OVERVIEW OF THE CONFERENCE GOALS – M. FISHER

SESSION 1 – “INTRODUCTION AND OVERVIEW OF CURRENT STROKE MODELS”
W. PULSINELLI and G. FEUERSTEIN

8:15 – 8:30 Mouse Stroke Models, Including Transgenics – P. Chan
8:30 – 8:45 Rat Stroke Models – C. Hsu
8:45 – 9:00 Cat Stroke Models – R. Traystman
9:00 – 9:15 Primate Stroke Models – G. del Zoppo
9:15 – 9:30 Embolic Stroke Models – M. Chopp
9:30 – 10:30 Discussion – Moderated by W. Pulsinelli and G. Feuerstein

10:30 – 10:45 Break

SESSION 2: “HOW TO BEST MAKE ANIMAL DRUG ASSESSMENT RELEVANT TO CLINICAL STROKE THERAPY DEVELOPMENT”
M. MOSKOWITZ, and J. CLEMENS

10:45 – 11:00 Physiological Monitoring Standards and Recommendations on the Length of Animal Survival – A. Buchan
11:00 – 11:15 Behavioral Outcome Measurements – What to use and When – D. Dietrich
11:15 – 11:30 The Therapeutic Time Window and Stroke Models – M. Ginsburg
11:45 – 12:45 Discussion – Moderated by M. Moskowitz and J. Clemens

12:45 – 1:45 Lunch
SESSION 3: “HOW TO PROCEED FROM PRECLINICAL TO CLINICAL DRUG DEVELOPMENT” – J. ZIVIN and B. STEIGER

1:45 – 2:00 What Type of Preclinical Data would Clinical Stroke Neurologists like Demonstrated before beginning Clinical Trials – R. Sacco, G. Albers

2:00 – 2:15 How to Relate the Preclinical Pharmacological Profile to Clinical Drug Development – J. McCulloch

2:15 – 2:30 Lessons for Preclinical Drug Development from Recent Clinical Trials – E. Hall

2:30 – 2:45 What Type of Preclinical Data would Upper Management in the Pharmaceutical Industry like to help make Decisions about Clinical Development – D. Levy

2:45 – 3:00 An NINDS Perspective on Animal Modeling to Develop Acute Stroke Therapies – J. Marler

3:00-3:20 Are Surrogate Markers Useful in Preclinical and Clinical Stroke Drug Development – M. Moseley, S. Warach

3:20 – 4:00 Discussion – Moderated by J. Zivin and B. Steiger

4:00 – 4:15 Break

SESSION 4: “RESTORATIVE THERAPY FOR ISCHEMIC STROKE”
L. GOLDSTEIN and J. BOGOUSSALAVSKY

4:15 – 4:30 Functional Recovery Following Brain Injury in Rats – Role of New Neuronal Sprouting – T. Schallert

4:30 – 4:45 Reorganization of Sensorimotor Cortex in Monkeys following Ischemic Injury – R. Nudo

4:45 – 5:00 Polypeptide Growth Factors in Stroke Recovery – their Role as potential Therapeutic Agents – S. Finklestein

5:00-5:15 Clinical Tools for Assessment of Stroke Recovery – S. Cramer

5:15 – 5:45 Discussion

7:00 – 9:00 Dinner (on site)

9:00 – 9:30 How does the Pharmaceutical Industry view the failure of Stroke Models to Predict Clinical Trial Outcome – F. Marcoux (Park-Davis)
“Stroke Drug Development: Bridging the Gap from Animal Research to Human Trials”

Sunday, March 7th

8:00 – 10:00 WORKING BREAKFAST FOCUS GROUPS WITH PARTICIPANTS DIVIDED INTO THREE GROUPS – EACH GROUP TO DEVELOP A REPORT


GROUP 2: Recommendations for how best to use Animal Modeling to Develop Restorative Drug Therapy for Acute Ischemic Stroke – Chairmen: P. Gorelick and S. Finklestein

GROUP 3: Recommendations to Clinicians concerning how to assess the Relevance and Appropriateness of Preclinical Stroke Drug Evaluations – Chairmen: A. Furlan and K. Lees

10:00 – 10:30 Break – Reconvene All Attendees

10:30 – 12:00 Presentation of the Recommendations from the Three Focus Groups and General Discussion – Chaired by M. Fisher, S. Finklestein and R. Traystman

12:00 – 2:00 Working Lunch. Begin to Draft a Consensus Document covering the Four Main Charges of the Conference

2:00 Adjournment

—— Thank You for Your Participation ——